Abstract
Beta-blockers are important for severe-status patients with atrial fibrillation-related tachycardia. Beta 1-selective intravenous injection are routinely used, but long-term administration is difficult due to cost-performance- or management-related issues. A bisoprolol patch, a beta-blocker to be percutaneously absorbed, recently became commercially available in Japan. As it may facilitate effective absorption and a mild elevation of the blood concentration, we retrospectively analyzed 16 patients with atrial fibrillation-related tachycardia who were admitted to the Intensive Care Unit of Hitachi General Hospital Emergency and Critical Care Center, and underwent switching therapy from landiolol to a bisoprolol patch. For switching, the bisoprolol patch (4 mg) was attached to each patient. The bisoprolol patch was introduced 88 h after the start of landiolol administration, when the rate was approximately 3 μg/kg/min. Landiolol injection was combined with bisoprolol for 15.4 ± 17.5 h. Switching therapy was successful in all subjects. The introduction of the bisoprolol patch did not induce any significant changes in the blood pressure or heart rate. After the completion of landiolol administration, there were also no significant changes in either parameter. There were no adverse events. In severe-status patients, switching therapy from landiolol injection to the bisoprolol patch can be conducted safely, and might be useful for heart-rate control.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rawles JM. What is meant by a “controlled” ventricular rate in atrial fibrillation? Br Heart J. 1990;63(3):157–61.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47
Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(24):2215–45
Muller-Werdan U, Buerke M, Ebelt H, Heinroth KM, Herklotz A, Loppnow H, Ruß M, Schlegel F, Schlitt A, Schmidt HB, Söffker G, Werdan K. Septic cardiomyopathy—a not yet discovered cardiomyopathy? Exp Clin Cardiol. 2006;11(3):226–36
Murakami M, Furuie H, Matsuguma K, Wanibuchi A, Kikawa S, Irie S. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta 1-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metab Pharmacokinet. 2005;20(5):337–44.
Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013;73(9):959–77.
Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth. 2001;48(10):985–9.
Ikeshita K, Nishikawa K, Toriyama S, Yamashita T, Tani Y, Yamada T, Asada A. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22(4):361–6.
Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fu**o K, Nagano T, Okamura T, Hori M, J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta 1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908–16.
Kobayashi S, Murakami W, Myoren T, Tateishi H, Okuda S, Doi M, Nao T, Wada Y, Matsuzaki M, Yano M. A low-dose beta 1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology. 2014;127(2):105–13.
Yamashita T, Inoue H. Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study. J Cardiol. 2013;62(1):50–7.
Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T. Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. J Clin Hypertens (Greenwich). 2013;15(11):806–14.
London MJ. Perioperative beta-blockade, discontinuation, and complications: do you really know it when you see it? Anesthesiology. 2009;111(4):690–4.
Ross PJ, Lewis MJ, Sheridan DJ, Henderson AH. Adrenergic hypersensitivity after beta-blocker withdrawal. Br Heart J. 1981;45(6):637–42.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
About this article
Cite this article
Nakamura, K., Inokuchi, R., Hiruma, T. et al. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J Anesth 30, 891–894 (2016). https://doi.org/10.1007/s00540-016-2199-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00540-016-2199-9